Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Background: Daratumumab, lenalidomide and dexamethasone (DRd) bortezomib, (VRd) are preferred regimens for transplant ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Both DRd VRd demonstrated superior efficacy vs. Rd in the MAIA SWOG S0777 trials, respectively, but there is no head-to-head (H2H) clinical trial comparing their efficacy. Differing populations trials make an unadjusted comparison of outcomes challenging biased. The current TAURUS study first real-world H2H progression-free survival (PFS) among TIE NDMM treated or as first-line (1L) similar settings.Materials Methods: A multicenter chart review was conducted at nine sites across US. All a randomly selected population were included. aged ≥65 included if they initiated 1L DRd/VRd between January 2019 September 2021. PFS defined time from initiation until disease progression death. doubly-robust multivariable Cox regression model combined inverse probability treatment weighting (IPTW) methodology used to compare cohorts.Results: Weighted cohorts comprised 91 87 patients. Thirteen 24 experienced progression/death. Patients had lower risk progression/death (adjusted hazard ratio: 0.35, 95% confidence interval: [0.17; 0.73]).Conclusion: associated significantly death compared patients.Micro-AbstractDaratumumab, lenalidomide, transplant-ineligible myeloma, these regimens. This therapy. VRd.